New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT06178159
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a combination of three drugs—disitamab vedotin, pertuzumab, and toripalimab—can shrink or eliminate HER2-positive breast tumors before surgery. About 40 adults with early-stage breast cancer will receive the drugs intravenously for 18 weeks, then have surgery. The main goal is to see if the cancer is completely gone at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disitamab vedotin, pertuzumab, and toripalimab (drugs given intravenously)
What this could lead to
If successful, this could lead to a more effective pre-surgery treatment for HER2-positive breast cancer, potentially improving the chance of eliminating all cancer before surgery.
What could go wrong
This is an early Phase 2 trial with only 40 participants, so results may not apply to all patients. The combination of drugs may cause side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact